Full Answer
What is the Uptravi® Patient Guide?
This guide helps you set goals and expectations with patients who are starting treatment with UPTRAVI®. It can be used as a conversation tool and is available to patients to help them stay on treatment by tracking and sharing how they’re feeling with their healthcare team.
What is Uptravi® IASSIST?
UPTRAVI® may now be prescribed through iAssist, a web-based platform that streamlines the prescription and enrollment process. Instead of faxing individual enrollment forms and insurance information, data can be entered in one place online to minimize incomplete forms and multiple submissions.
Is there an alternate form for the Uptravi psmn form?
Note: An alternate form is available for Veteran Affairs (VA) patients UPTRAVI® VA Prescription and Statement of Medical Necessity Form. This guide provides detailed instructions to help you fill out the UPTRAVI® PSMN Form.
What is Uptravi used to treat?
What is UPTRAVI®? UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs. UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.
What is the cost of Selexipag?
Uptravi (selexipag) is a member of the agents for pulmonary hypertension drug class and is commonly used for Pulmonary Hypertension....Oral Tablet.QuantityPer unitPrice60$356.00$21,359.80
Who manufactures Uptravi?
UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Ltd. 2.
How is Uptravi administered?
How is selexipag (Uptravi®) given? Selexipag is an oral tablet given by mouth. The starting dose of selexipag is 200 mcg twice daily. The dose is then increased by 200mcg twice daily every week to the highest dose a patient can tolerate up to a maximum dose of 1,600mcg twice daily.
Is there a generic for Uptravi?
No. There is currently no therapeutically equivalent version of Uptravi available in the United States. Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Uptravi. These medications may be counterfeit and potentially unsafe.
What class of drug is Uptravi?
Uptravi is a prescription medicine used to treat the symptoms of Pulmonary Arterial Hypertension (PAH) Disease Progression. Uptravi may be used alone or with other medications. Uptravi belongs to a class of drugs called PAH, Prostacyclin Agonists.
Does UPTRAVI lower blood pressure?
Uptravi lowers blood pressure in your lungs by dilating (widening) blood vessels that supply blood to the lungs. Uptravi is used to treat pulmonary arterial hypertension (PAH). Uptravi helps keep your condition from getting worse and helps lower your risk of needing to be hospitalized for PAH.
What is the difference between UPTRAVI and Opsumit?
Uptravi and Opsumit belong to different drug classes. Uptravi is a prostacyclin receptor agonist and Opsumit is an endothelin receptor antagonist. Side effects of Uptravi and Opsumit that are similar include headache and low levels of iron in the blood (anemia).
What are the 5 types of pulmonary hypertension?
The Five GroupsGroup 1: Pulmonary Arterial Hypertension (PAH) ... Group 2: Pulmonary Hypertension Due to Left Heart Disease. ... Group 3: Pulmonary Hypertension Due to Lung Disease. ... Group 4: Pulmonary Hypertension Due to Chronic Blood Clots in the Lungs. ... Group 5: Pulmonary Hypertension Due to Unknown Causes.More items...•
Can Selexipag be crushed?
During photostability studies, it was demonstrated that the selexipag core tablets are sensitive to light. In order to protect the core tablet from light-induced degradation, an appropriate film coating was developed and applied. Tablets should not be split, crushed or chewed, and are to be swallowed with some water.
How is Selexipag administered?
Administer UPTRAVI® for injection twice daily by intravenous infusion at a dose that corresponds to the patient's current dose of UPTRAVI® Tablets (see Table 1 in full Prescribing Information). Administer UPTRAVI® for injection as an 80-minute intravenous infusion.
Is UPTRAVI a brand name?
Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH).
Is UPTRAVI a specialty drug?
UPTRAVI® is not available through retail pharmacies. UPTRAVI® is distributed to patients by mail through a specialty pharmacy rather than through a retail pharmacy. When you enroll your patients, they are connected to a specialty pharmacy based on their health insurance plans or their healthcare teams' preference.
Does Opsumit lower blood pressure?
Macitentan lowers blood pressure in your lungs, helping your heart pump blood more efficiently. Macitentan is used to treat pulmonary arterial hypertension (PAH). It improves your ability to exercise and prevents your condition from getting worse.
Does Adempas lower blood pressure?
Adempas reduces blood pressure, which may cause symptoms such as lightheadedness, chest pain, dizziness, and fainting; consult with your healthcare provider.
What is Uptravi guide?
This guide helps you set goals and expectations with patients who are starting treatment with UPTRAVI. It can be used as a conversation tool and is available to patients to help them stay on treatment by tracking and sharing how they’re feeling with their healthcare team.
How much does Janssen CarePath save?
Depending on their health insurance plan, savings may apply toward co-pay, co-insurance, or deductible. Your eligible patients will pay $5 per prescription fill with a $20,000 maximum program benefit per calendar year across all oral PAH therapies in the program. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement. See full eligibility requirements at Uptravi.JanssenCarePathSavings.com.
Is Uptravi a web based program?
UPTRAVI may now be prescribed through iAssist, a web-based platform that stream lines the prescription and enrollment process. Instead of faxing individual enrollment forms and insurance information, data can be entered in one place online to minimize incomplete forms and multiple submissions.
How much does Uptravi cost?
Eligible patients using commercial or private insurance can save on out-of-pocket medication costs for UPTRAVI. Eligible patients pay $5 per prescription fill with a $20,000 maximum program benefit per calendar year across all oral PAH therapies in the program. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement.
What is UPTRAVI used for?
UPTRAVI ® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs. UPTRAVI can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.
How to report UPTRAVI side effects?
You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Keep UPTRAVI and all other medicines away from children.
What is a PAH companion program?
The Janssen CarePath PAH Companion Program provides one-on-one educational support to help you start and stay on your prescribed Janssen medication and resources to help you partner with your healthcare team to better manage your pulmonary arterial hypertension (PAH).
How often should I take Uptravi?
Take UPTRAVI exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI twice a day. Taking UPTRAVI with food may help you tolerate UPTRAVI better
How to talk to a PAH companion?
Patients who have enrolled can talk to a PAH Companion by calling 1-866-300-1818, Mon-Fri, 8 AM -9 PM ET.
How to contact Janssen Carepath?
Call a Janssen CarePath Care Coordinator at 866-228-3546 or visit JanssenCarePath.com for more information about affordability programs and independent foundations † that may have funding available. †Independent co-pay assistance foundations have their own rules for eligibility.
What is Uptravi patient guide?
A patient guide that highlights the important steps and information about titration with UPTRAVI ®.
What is UPTRAVI used for?
UPTRAVI ® (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
How many times can you increase uptravi?
Increase UPTRAVI ® dose, up to twice , when co-administered with rifampin. Reduce UPTRAVI ® when rifampin is stopped.
How often should I take Uptravi?
Administer UPTRAVI ® for injection twice daily by intravenous infusion at a dose that corresponds to the patient’s current dose of UPTRAVI ® Tablets (see Table 1 in full Prescribing Information). Administer UPTRAVI ® for injection as an 80-minute intravenous infusion.
What is a PAH companion?
The Janssen CarePath PAH Companion* Program provides one-on-one educational support to help patients start and stay on their prescribed Janssen medication and resources to help them partner with their healthcare team to better manage their pulmonary arterial hypertension (PAH).
What is the phone number for PAH?
As part of the program, PAH Companions are ready to answer patients’ questions. Patients who have enrolled can talk to a PAH Companion by calling 866-300-1818, Monday-Friday, 8 AM to 9 PM ET.
Does Uptravi cause hyperthyroidism?
Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI ® Tablets and in none of the patients on placebo.
Resources
The following resources are designed to help you as you start treatment with UPTRAVI ®. You will also find common questions and answers about Janssen CarePath and UPTRAVI ® .
Enrollment
Patient Authorization Form [PDF] - Allows you to authorize the use of your personal information for Janssen patient support programs.
Patient Support
Dose Adjustment Phase Guide [PDF] - A guide that highlights important steps and information about titration with UPTRAVI ® .
Cost Support
Janssen CarePath Oral PAH Savings Program Overview [PDF] - Provides information on the Janssen CarePath Savings Program for UPTRAVI ® and eligibility requirements for enrolling in the program.
Coverage
Medicare Open Enrollment Guide [PDF] - Even if you keep the same health plan, your benefits can change. This guide can help you review your coverage and make changes if needed during the open enrollment period so you can stay on treatment in the new benefit period.
Johnson & Johnson Patient Assistance Foundation, Inc
Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) - An independent, nonprofit organization that gives eligible patients free prescription medicines donated by Johnson & Johnson companies.
Welcome to Janssen CarePath
Janssen CarePath is here to help answer your questions about treatment with UPTRAVI ®. Once you and your doctor have decided UPTRAVI ® is right for you, we will give you resources that may help you get started and stay on track.
Getting Started
Janssen CarePath can review your health plan benefits and insurance coverage for UPTRAVI ® and offer treatment education resources.
Staying on Track
We understand how important it is for you to take the Janssen medication your doctor prescribed. Janssen CarePath provides ongoing support that may help you stay on track with your UPTRAVI ® treatment.
Resources
Documents and websites to help you with cost support, coverage, and more.
What is UPTRAVI used for?
UPTRAVI ® (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
How much uptravi should I take daily?
Recommended starting dose is 200 mcg twice daily for UPTRAVI ® Tablets. Tolerability may be improved when taken with food. Increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcg twice daily. If dose is not tolerated, reduce to the previous tolerated dose.
How many times can you increase uptravi?
Increase UPTRAVI ® dose, up to twice , when co-administered with rifampin. Reduce UPTRAVI ® when rifampin is stopped.
How often should I take Uptravi?
Administer UPTRAVI ® for injection twice daily by intravenous infusion at a dose that corresponds to the patient’s current dose of UPTRAVI ® Tablets (see Table 1 in full Prescribing Information). Administer UPTRAVI ® for injection as an 80-minute intravenous infusion.
What percentage of patients had idiopathic and heritable PAH?
Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), and PAH associated with congenital heart disease with repaired shunts (10%).
Is Uptravi effective in PAH?
Effectiveness of UPTRAVI ® Tablets was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms.
Does Uptravi cause hyperthyroidism?
Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI ® Tablets and in none of the patients on placebo.
What is UPTRAVI used for?
What is UPTRAVI ® (selexipag)? UPTRAVI ® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1) , which is high blood pressure in the arteries of your lungs.
How to report side effects of Uptravi?
The most common side effects are: Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI ®. For more information, ask your doctor or pharmacist. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Can Uptravi cause side effects?
UPTRAVI® and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor.
Is Uptravi safe for children?
UPTRAVI ® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH. It is not known if UPTRAVI ® is safe and effective in children. Important Safety Information For UPTRAVI ®.
What is The Patient Assistance Program?
The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, non-profit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies.
Program Update
Patients may now choose the option of electronic income verification. Instead of submitting a copy of their Federal tax return, they can simply check a box on the updated application form.
Contraindications
Warnings and Precautions
- Should signs of pulmonary edema occur, consider the possibility of associated PVOD. If confirmed, discontinue UPTRAVI®.
Adverse Reactions
- Adverse reactions more frequent compared to placebo (≥3%) are headache (65% vs 32%), diarrhea (42% vs 18%), jaw pain (26% vs 6%), nausea (33% vs 18%), myalgia (16% vs 6%), vomiting (18% vs 9%), pain in extremity (17% vs 8%), flushing (12% vs 5%), arthralgia (11% vs 8%), anemia (8% vs 5%), decreased appetite (6% vs 3%), and rash (11% vs 8%). These adverse reactions are …
Drug Interactions
- Concomitant administration with gemfibrozil, a strong inhibitor of CYP2C8, doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Concomitant use of UPTRAVI® with strong inhibitors of CYP2C8 is contraindicated. Concomitant administration of UPTRAVI® with clopidogrel, a moderate inhibitor of CYP2C8, had no relevant e…
Dosage and Administration
- Recommended starting dose is 200 mcg twice daily. Tolerability may be improved when taken with food. Increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcg twice daily. If dose is not tolerated, reduce to the previous tolerated dose. For patients with moderate hepatic impairment (Child-Pugh class ...
Drug Interactions
- CYP2C8 Inhibitors
Concomitant administration with gemfibrozil, a strong inhibitor of CYP2C8, doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Concomitant use of UPTRAVI®with strong inhibitors of CYP2C8 is contraindicated. Concomitant administrati… - CYP2C8 Inducers
Concomitant administration with an inducer of CYP2C8 and UGT 1A3 and 2B7 enzymes (rifampin) halved exposure to the active metabolite. Increase UPTRAVI® dose, up to twice, when co-administered with rifampin. Reduce UPTRAVI®when rifampin is stopped.
Dosage and Administration
- Recommended Dosage
Recommended starting dose is 200 mcg twice daily for UPTRAVI® Tablets. Tolerability may be improved when taken with food. Increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcgtwice daily. If dose is not tolerated, reduce to the previ… - Patients With Hepatic Impairment
For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose of UPTRAVI® Tablets is 200 mcg once daily. Increase by 200 mcg once daily at weekly intervals, as tolerated. Avoid use of UPTRAVI®in patients with severe hepatic impairment (Child-Pugh class C).
Additional Important Safety Information For Uptravi® IV
- Use UPTRAVI®for injection in patients who are temporarily unable to take oral therapy. Administer UPTRAVI® for injection twice daily by intravenous infusion at a dose that corresponds to the patient’s current dose of UPTRAVI® Tablets (see Table 1 in full Prescribing Information). Administer UPTRAVI®for injection as an 80-minute intravenous infusion. Adverse Reactions: Inf…